# NM_000155.4(GALT):c.24T>G (p.Pro8=)

https://sugi.bio/variant/galt-p-pro8

## Summary

**GALT p.Pro8= (c.24T>G)** is classified **Likely benign** in GALT (ClinVar, Single submitter, 1 submitter; last evaluated 2025-05-03). Very rare (popmax 8.47e-05%, nfe); Associated with classic galactosemia.

**At a glance:** Likely benign · review: Single submitter · rsID rs147803976 · 1 submitter · 1 linked condition · very rare (popmax 8.47e-05%, nfe)

## For patients & families {#patients}

This is a change in the GALT gene that is classified as likely benign — not considered disease-causing, submitted by 1 submitter, and is linked to classic galactosemia.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

|  |  |
| --- | --- |
| Typical inheritance (of this condition) | Autosomal recessive |
| Age of onset (of this condition) | Infancy, Neonatal |
| Prevalence | 1-9 / 100 000 (Europe) |
| Clinical trials | 5 registered for this condition — see ClinicalTrials.gov |
| Diagnostic panels | GALT is a diagnostic-grade gene on 13 Genomics England panels |

**Commonly reported features of Classic galactosemia** (across patients with this condition; presentation varies — frequencies from Orphanet):

- Abnormality of the nervous system — Very frequent (99-80%)
- Male infertility — Very frequent (99-80%)
- Abnormal enzyme/coenzyme activity — Very frequent (99-80%)
- Abnormal erythrocyte enzyme activity — Very frequent (99-80%)
- Cataract — Frequent (79-30%)
- Delayed speech and language development — Frequent (79-30%)
- Primary amenorrhea — Frequent (79-30%)
- Delayed puberty — Frequent (79-30%)

**Support & next steps:** [Condition overview & support (NIH GARD)](https://rarediseases.info.nih.gov/diseases/0013639/index) · [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [GALT](https://sugi.bio/atlas/gene/GALT/) |
| Protein change (HGVS p.) | p.Pro8= |
| Coding change (HGVS c.) | c.24T>G |
| MANE Select transcript | [NM_000155](https://www.ncbi.nlm.nih.gov/nuccore/NM_000155) |
| dbSNP | [rs147803976](https://www.ncbi.nlm.nih.gov/snp/rs147803976/) |
| Variant type | single nucleotide variant |
| Location | chr9:34646728-34646728 (GRCh38) |
| ClinVar | [VCV2420570](https://www.ncbi.nlm.nih.gov/clinvar/variation/2420570/) |

**All HGVS expressions:** `NC_000009.11:g.34646725T>G`, `NC_000009.12:g.34646728T>G`, `NG_009029.2:g.5140T>G`, `NM_000155.4:c.24T>G`, `NM_001258332.2:c.-179T>G`

## Computational & population evidence {#evidence}

**Concordance:** Mixed / partial computational evidence (see below).

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation (below), not from a missing predictor score.
- Conservation: phyloP -5.123, GERP -4.03 — fast-evolving / accelerated position
- CADD: **PHRED 1.34**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI: **not assessed** — no allele at this position is in our SpliceAI release, either because it lies outside the scored MANE transcript scope or because every allele is below Δ0.2. We cannot tell which, so this claims neither; absence is not evidence against a splicing effect.
- Population frequency (gnomAD v4.1): grpmax **8.47e-05%** (nfe) · 1/1,179,976 in the highest group · 1/1,613,664 alleles overall — very rare (popmax 8.47e-05%, nfe).

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**GALT** population constraint: LOEUF 0.935, pLI 4.2797e-11, missense-Z 1.8721; ClinGen dosage — haploinsufficiency gene assoc. with recessive phenotype, triplosensitivity Not yet evaluated/3. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

## Protein context {#protein}

Residue **8** lies in the 'disordered' region.

AlphaFold model confidence (whole protein): pLDDT 92.08, 81% of residues very-high.

**2 experimental structure(s)** (PDB): [5IN3](https://www.rcsb.org/structure/5IN3), [6GQD](https://www.rcsb.org/structure/6GQD).

## What this gene does {#gene-function}

*Describes the biological roles of GALT (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** GALT's established molecular role includes UDP-glucose:hexose-1-phosphate uridylyltransferase activity. p.Pro8= falls in the disordered region. In Reactome, GALT is annotated in disease pathway(s) including **Defective GALT can cause GALCT**.

**Disease mechanism (Reactome):** GALT loss or alteration is curated in [Defective GALT can cause GALCT](https://reactome.org/content/detail/R-HSA-5609978).

### Pathways affected {#pathways}

GALT participates in **2 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| ⚕ [Defective GALT can cause GALCT](https://reactome.org/content/detail/R-HSA-5609978) | curated |
| [Galactose catabolism](https://reactome.org/content/detail/R-HSA-70370) | curated |

### Molecular function & processes (GO — experimentally supported) {#go}

**Molecular function:** UDP-glucose:hexose-1-phosphate uridylyltransferase activity, zinc ion binding.

**Biological process:** UDP-alpha-D-glucose metabolic process, galactose metabolic process.

## Clinical significance {#significance}

**Likely benign** — review status Single submitter *(criteria provided, single submitter)*, last evaluated 2025-05-03.

**Submitter consensus:** unanimous (1/1 Likely benign).

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Labcorp Genetics (formerly Invitae), Labcorp | Likely benign | criteria provided, single submitter | clinical testing | 2025-05-03 |

## Associated conditions {#conditions}

[classic galactosemia](https://sugi.bio/atlas/disease/classic-galactosemia/).

**Reported phenotype names (ClinVar):** Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase, GALT deficiency, Galactosemia, classic, GALACTOSEMIA I, GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE DEFICIENCY, Transferase Deficiency Galactosemia.

## Similar variants {#similar}

Related GALT variant pages (same residue, condition, or type): [GALT p.Pro8Leu](/variant/galt-p-pro8leu), [GALT c.1060-1G>A](/variant/galt-c-1060-minus-1g-a), [GALT c.252+1G>A](/variant/galt-c-252-plus-1g-a), [GALT c.253-1G>A](/variant/galt-c-253-minus-1g-a), [GALT c.253-2A>G](/variant/galt-c-253-minus-2a-g), [GALT c.328+2T>G](/variant/galt-c-328-plus-2t-g), [GALT c.329-2A>C](/variant/galt-c-329-minus-2a-c), [GALT c.377+1G>A](/variant/galt-c-377-plus-1g-a).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-06); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 2420570). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*